Healthtech

ChemT Biotechnology, an AI-driven biotechnology company based on Singapore, has closed a $4 million seed round led by Wavemaker Ventures and co-investment partner SEEDS, an arm of SG Growth Capital, with support from Wavemaker 360 Health, Draper University Ventures, and Temasek Life Sciences Accelerator.

Ovum, an Australian women's health company founded by Ariella Heffernan-Marks, has raised $4 million in seed funding to address the gender health gap, tripling its valuation just one year after securing $1.7 million in a pre-seed round.

Japan's Murata Electronics and Signapore-based Tribe, an open innovation platform, have launched KUMIHIMO Tech Camp Singapore 2026, an open innovation programme inviting MedTech startups across ASEAN and India to co-develop healthcare solutions addressing the region's most pressing medical challenges.

Brano Therapeutics, a spin-off from Singapore's Duke-NUS Medical School, has secured $6.8 million in seed funding to support the development of new treatments for heart failure, including heart failure with preserved ejection fraction (HFpEF), a condition with limited therapeutic options.

The discussion started with a light conversation over the use of modern tools like ChatGPT in healthcare. It proceeded to highlight why healthcare is a leading priority for investors in Southeast Asia. Additionally, the panel pointed out the challenges and opportunities as well as the potential for innovative technologies.

We envision Seedstars to be at the forefront of driving entrepreneurship and investment in emerging markets. We aim to expand our footprint, invest in more startups, and empower more entrepreneurs through our educational programs.

Ami's end goal is to make tangible improvements in the well-being of employees compared to the other underutilized or ineffective wellness solutions used by companies.

DA has built a strong ecosystem of payers, providers, and patients across its core markets. It has close to 2,800 doctors and medical professionals within its network in the region, and it also works closely with major hospitals and healthcare institutions. 

Led by CR-CP Life Science Fund, this new capital will support MiRXES’s growth as a global leader in cancer early detection tests and preventive healthcare.